BioWorld MedTech

Sep. 1, 2017

View Archived Issues

Abbott seeks indication for Amplatzer to treat heart defects in pre-term infants

Abbott Laboratories has initiated a U.S. pivotal clinical study evaluating a modified version of its Amplatzer device designed to correct a common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year. Read More

Researchers behind newly funded Neuros get $2M from NIH for nerve-block studies

Read More

Hologic's Brevera biopsy system hits U.S. market

Read More

CDSC inks voluntary guidelines for medium-risk CDS systems

Read More

New factor helps old iPSCs

Read More

Holiday notice

Read More

Product briefs

Read More

Other news to note

Read More

Regulatory front

Read More

BioWorld MedTech's Diagnostics Extra

Read More